Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer.
about
Unique growth pattern of human mammary epithelial cells induced by polymeric nanoparticlesIron and cancer: more ore to be mined.Ell3 stimulates 5-FU resistance in a breast cancer cell line.Serum autoantibodies in pristane induced lupus are regulated by neutrophil gelatinase associated lipocalinOestrogen-induced angiogenesis promotes adenomyosis by activating the Slug-VEGF axis in endometrial epithelial cells.Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunitiesObesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality.Down-regulation of neutrophil gelatinase-associated lipocalin in head and neck squamous cell carcinoma correlated with tumorigenesis, not with metastasis.Increased Obesity-Associated Circulating Levels of the Extracellular Matrix Proteins Osteopontin, Chitinase-3 Like-1 and Tenascin C Are Associated with Colon CancerICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-angiogenic Agents for Triple Negative Breast CancerThe endogenous zinc finger transcription factor, ZNF24, modulates the angiogenic potential of human microvascular endothelial cells.Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer.Overexpression of lipocalin 2 in human cervical cancer enhances tumor invasion.Cellular iron metabolism in prognosis and therapy of breast cancer.Tpl2 inhibitors thwart endothelial cell function in angiogenesis and peritoneal dissemination.Help-me signaling: Non-cell autonomous mechanisms of neuroprotection and neurorecovery.Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.Identification of novel non-invasive biomarkers of urinary chronic pelvic pain syndrome: findings from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network.Neutrophil gelatinase-associated lipocalin and its influence on tumor progression in systemic malignancies.Comparison of the Adipose and Luminal Mammary Gland Compartment as Orthotopic Inoculation Sites in a 4T1-Based Immunocompetent Preclinical Model for Triple-Negative Breast Cancer.Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.Lipocalin-2 deficiency or blockade protects against aortic abdominal aneurysm development in mice.Macrophage-derived lipocalin-2 transports iron in the tumor microenvironment.Targeting delivery of lipocalin 2-engineered mesenchymal stem cells to colon cancer in order to inhibit liver metastasis in nude mice.Lipocalin 2 from macrophages stimulated by tumor cell-derived sphingosine 1-phosphate promotes lymphangiogenesis and tumor metastasis.High-Dose Deferoxamine Treatment Disrupts Intracellular Iron Homeostasis, Reduces Growth, and Induces Apoptosis in Metastatic and Nonmetastatic Breast Cancer Cell Lines.Alterations in Cellular Iron Metabolism Provide More Therapeutic Opportunities for Cancer.
P2860
Q28391186-6F320CE9-BAC7-4824-BE0C-A7AA8EAF1289Q33677592-A9194ADA-47B4-4E26-847A-29C22EFFEF7CQ33750730-A053CD68-69E6-42CD-B77B-EF1643F29620Q33992328-001CEA36-7892-47EA-B72E-C7A254637881Q34011486-CA31176C-586F-4AF9-A836-E4960E25D2D2Q35034547-8BB3A98C-A48C-4C85-8E7A-0181843364A0Q35817986-DB13B4E0-01B3-4581-A3B8-329EB5DF22BFQ36095074-E80A4753-4C1C-4ECF-928B-F9DB8BFF20D4Q36128631-2CFCAC56-602F-4C31-B89E-B4548CEAD446Q36372319-84259039-A95F-427C-A18F-5975F809EC1EQ36525804-72CCB148-A2CD-4577-BF45-D47D9700DC4AQ36557683-506AF140-9276-42CB-BE9D-E0F8D7F257AEQ36998174-94D6945C-8570-44CF-B4C6-E7EA44F6B28CQ37077422-AA4DA4F5-15BD-494A-B874-002AAAA94026Q37162383-FE934B64-5B1F-4FB8-99A6-60A300E3B632Q38808589-1DD110A1-A2EA-4A35-9374-2311C2D243E2Q38904753-0ABB508E-8111-44E3-AB2D-77BCB3D45DFCQ40306598-D8115846-B09E-4B98-8E4C-D563A9DCC4D8Q44151403-2D2580A0-B0F5-499B-9FE8-8629BCE1ECAAQ45858997-B047465F-FAE6-4C84-8754-D470EBA29198Q47119535-93A78748-AE63-4E51-9610-3620ADDEB4A1Q50239051-FC7F5581-9223-4CDB-8EB9-67F2B9266F7BQ50420404-0CAA25B7-B445-4DBD-8CDB-2CF778F7AC77Q51001958-BBC84CBA-BE64-4E0E-9D13-AA0E8E63CF4BQ51676055-B68BA84F-D81F-4BF1-8035-80296E3F8B8DQ51737021-78ACA0DA-D89C-4CFA-800B-407B749AA83AQ55497286-EFCE419F-40B8-4359-85C1-58FC2DC548F5
P2860
Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer.
@ast
Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer.
@en
type
label
Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer.
@ast
Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer.
@en
prefLabel
Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer.
@ast
Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer.
@en
P2093
P2860
P356
P1433
P1476
Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer.
@en
P2093
Brendan McNeish
Catherine Butterfield
Jiang Yang
Marsha A Moses
P2860
P356
10.1096/FJ.12-211730
P407
P577
2012-09-14T00:00:00Z